title: Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemide.
abstract: Pharmacodynamic effects of combination therapy with omapatrilat and furosemide were evaluated. Two groups of 13 healthy subjects each received furosemide 20 mg dailyfor 15 days coadministered with either placebo on days 6 to 15 or omapatrilat 10 mg on days 6 to 10 and 25 mg on days 11 to 15. In the omapatrilat group, urinary excretion of atrial natriuretic peptide increased, and greater blood pressure reductions were seen compared with placebo. Concomitant omapatrilat treatment did not affect the acute diuresis, natriuresis, and kaliuresis observed with chronic administration of furosemide. Neither effective renal plasma flow nor glomerularfiltration rate changed in either treatment group. No clinically significant safety issues were observed. Daily coadministration of omapatrilat 10 or 25 mg with furosemide 20 mg does not affect the pharmacodynamics offurosemide at steady state.
authors.affiliation: Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA.
authors.forename: H
authors.initials: H
authors.lastname: Uderman
authors.forename: O
authors.initials: O
authors.lastname: Vesterqvist
authors.forename: J
authors.initials: J
authors.lastname: Manning
authors.forename: I
authors.initials: I
authors.lastname: Ferreira
authors.forename: C
authors.initials: C
authors.lastname: Delaney
authors.forename: W C
authors.initials: WC
authors.lastname: Liao
mesh_terms: D000328:Adult; D019540:Area Under Curve; D004231:Diuresis / Q000187:drug effects; D004232:Diuretics / Q000009:adverse effects / Q000494:pharmacology*; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D005665:Furosemide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000097:blood*; D011188:Potassium / Q000652:urine; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D012079:Renal Circulation / Q000187:drug effects; D013841:Thiazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D004232:Diuretics; D007328:Insulin; D018377:Neurotransmitter Agents; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D005665:Furosemide; D011188:Potassium